Larimar Therapeutics Revenue vs. EBITDA
| LRMR Stock | USD 6.33 0.17 2.76% |
Total Revenue | First Reported 2019-06-30 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
For Larimar Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Larimar Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Larimar Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Larimar Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Larimar Therapeutics over time as well as its relative position and ranking within its peers.
Larimar |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Larimar Therapeutics. If investors know Larimar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Larimar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Larimar Therapeutics is measured differently than its book value, which is the value of Larimar that is recorded on the company's balance sheet. Investors also form their own opinion of Larimar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Larimar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Larimar Therapeutics' market value can be influenced by many factors that don't directly affect Larimar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Larimar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Larimar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Larimar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Larimar Therapeutics EBITDA vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Larimar Therapeutics's current stock value. Our valuation model uses many indicators to compare Larimar Therapeutics value to that of its competitors to determine the firm's financial worth. Larimar Therapeutics is currently under evaluation in revenue category among its peers. It is rated third overall in ebitda category among its peers . At this time, Larimar Therapeutics' Total Revenue is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Larimar Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Larimar Revenue vs. Competition
Larimar Therapeutics is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 693.42 Million. Larimar Therapeutics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.
Larimar EBITDA vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Larimar Therapeutics |
| = | null |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Larimar Therapeutics |
| = | (41.45 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Larimar EBITDA Comparison
Larimar Therapeutics is currently under evaluation in ebitda category among its peers.
Larimar Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Larimar Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Larimar Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Larimar Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Larimar Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 81 K | 85 K | |
| Operating Income | -41.8 M | -43.8 M | |
| Income Before Tax | -36.9 M | -38.8 M | |
| Total Other Income Expense Net | 4.8 M | 5 M | |
| Net Loss | -36.9 M | -38.8 M | |
| Interest Income | 223.2 K | 365.6 K | |
| Net Loss | -40.7 M | -42.7 M | |
| Income Tax Expense | -1.3 M | -1.4 M | |
| Net Loss | -36.9 M | -38.8 M | |
| Non Operating Income Net Other | 1.3 M | 821.1 K | |
| Change To Netincome | 7.6 M | 8 M | |
| Net Loss | (0.84) | (0.88) | |
| Income Quality | 0.91 | 0.69 | |
| Net Income Per E B T | 1.11 | 1.08 |
Larimar Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Larimar Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Larimar Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Larimar Therapeutics' important profitability drivers and their relationship over time.
Use Larimar Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Larimar Therapeutics Pair Trading
Larimar Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.
The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Larimar Therapeutics position
In addition to having Larimar Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Funds Thematic Idea Now
Healthcare Funds
Funds or Etfs investing in medical and healthcare goods or services as well as hospital management or maintenance organizations. The Healthcare Funds theme has 35 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.